LBA52 Interim analysis of GALAXIES Lung-201: Phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced/metastatic (LA/M) PD-L1 high (TPS >/=50%) non-small cell lung cancer (NSCLC)

D.R. Spigel, Ernesto Korbenfeld, Hidetoshi Hayashi, R. Corre, B.C. Cho, A. Psyrri, M. Cobo Dols, Elena Parkhomenko, Diana E. Baxter, Neel Patel, Fabrizio Trinchese, Iván Díaz-Padilla, M. Reck

2024Annals of Oncology11 citationsDOI Open Access PDF

Topics & Concepts

MedicineInterim analysisOpen labelMetastatic adenocarcinomaInterimOncologyInternal medicineRandomized controlled trialAdenocarcinomaCancerArchaeologyHistoryLung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersLung Cancer Research Studies

LBA52 Interim analysis of GALAXIES Lung-201: Phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced/metastatic (LA/M) PD-L1 high (TPS &gt;/=50%) non-small cell lung cancer (NSCLC)

Topics & Concepts

LBA52 Interim analysis of GALAXIES Lung-201: Phase II, randomized, open-label platform study of belrestotug plus dostarlimab in patients (pts) with previously untreated locally advanced/metastatic (LA/M) PD-L1 high (TPS >/=50%) non-small cell lung cancer (NSCLC)